DPP3 as a Biomarker in Patients with Cardiovascular Critical Illness

This publication has 24 references indexed in Scilit:

• Targeting Dipeptidyl Peptidase 3 (DPP3) in Extreme-critically Ill Patients with Refractory Shock: First-in-Human Report on the Safety and Efficacy of an anti-DPP3 Antibody
  European Journal of Heart Failure, 2025
• High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH Trial
  Journal of Cardiac Failure, 2024
• Advances in the Staging and Phenotyping of Cardiogenic Shock
  JACC: Advances, 2022
• High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort
  British Journal of Anaesthesia, 2022
• SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies
  JACC, 2022
• Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
  European Journal of Heart Failure, 2021
• Cardio- and reno-protective effects of dipeptidyl peptidase III in diabetic mice
  Journal of Biological Chemistry, 2021
• Circulating Dipeptidyl Peptidase 3 and Alteration in Haemodynamics in Cardiogenic Shock: Results from the OptimaCC Trial
  European Journal of Heart Failure, 2019
• Circulating Dipeptidyl Peptidase 3 is a Myocardial Depressant Factor: Dipeptidyl Peptidase 3 Inhibition Rapidly and Sustainably Improves Haemodynamics
  European Journal of Heart Failure, 2019
• Identification of Dipeptidyl Peptidase III in Human Neutrophils
  Biochemical and Biophysical Research Communications, 2000